Our star products, Shuilinjia and Jinghua Weikang, are designed for liver protection and treatment of stomach diseases. Xiaokeqing and Difumi (minodronic acid tablets) have great potential in treating diabetes and osteoporosis. We are stepping up R&D of innovative drugs and re-development of major products focusing on fatty liver, drug-induced liver diseases, H. pylori infection, diabetes, ulcerative colitis, and other diseases. These initiatives will expand our product portfolio and serve patients with chronic diseases in all stages of diseases.